Scarica l'app Stockscreener
20.82
3.07%
-0.66
Dopo l'orario di chiusura:
20.85
0.03
+0.14%
Precedente Chiudi:
$21.48
Aprire:
$21.44
Volume 24 ore:
2.11M
Relative Volume:
1.14
Capitalizzazione di mercato:
$2.30B
Reddito:
$12.59M
Utile/perdita netta:
$-212.39M
Rapporto P/E:
-6.7481
EPS:
-3.0853
Flusso di cassa netto:
$-185.92M
1 W Prestazione:
-4.10%
1M Prestazione:
+21.83%
6M Prestazione:
+141.25%
1 anno Prestazione:
+97.72%
Intervallo 1D:
$20.21
$21.50
Intervallo di 1 settimana:
$20.21
$22.12
Portata 52W:
$5.1501
$25.30
Immunome Inc Stock (IMNM) Company Profile
Nome
Immunome Inc
Settore
Industria
Telefono
610-321-3700
Indirizzo
18702 N. CREEK PARKWAY, BOTHELL
Confronta IMNM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
20.82 | 2.37B | 12.59M | -212.39M | -185.92M | -3.0853 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Immunome Inc Stock (IMNM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-01 | Iniziato | Truist | Buy |
| 2025-09-22 | Iniziato | Goldman | Buy |
| 2025-09-05 | Iniziato | Craig Hallum | Buy |
| 2025-04-02 | Iniziato | Lake Street | Buy |
| 2024-11-08 | Iniziato | Stephens | Overweight |
| 2024-05-31 | Iniziato | Piper Sandler | Overweight |
| 2024-04-30 | Iniziato | JP Morgan | Overweight |
| 2024-04-15 | Iniziato | Guggenheim | Buy |
| 2024-01-29 | Iniziato | Leerink Partners | Outperform |
| 2023-12-19 | Iniziato | Wedbush | Outperform |
| 2021-10-29 | Iniziato | Cantor Fitzgerald | Overweight |
Mostra tutto
Immunome Inc Borsa (IMNM) Ultime notizie
Understanding the Setup: (IMNM) and Scalable Risk - Stock Traders Daily
Top Executive Makes Bold Move With Fresh Immunome Stock Purchase - TipRanks
Insider Buying: Clay Siegall Acquires Additional Shares of Immunome Inc (IMNM) - GuruFocus
Immunome (NASDAQ:IMNM) CEO Purchases $100,018.35 in Stock - MarketBeat
Immunome (IMNM) CEO Siegall buys $100k in shares By Investing.com - Investing.com Nigeria
Immunome (IMNM) CEO Siegall buys $100k in shares - Investing.com India
Analysts Are Bullish on These Healthcare Stocks: Natera (NTRA), Immunome (IMNM) - The Globe and Mail
Why Immunome stock surged today - MSN
Immunome (IMNM): Assessing Valuation After Strong Phase 3 Varegacestat Data and $400 Million Equity Raise - Sahm
Immunome (IMNM) price target increased by 33.44% to 34.94 - MSN
Immunome, a top 3% stock, just delivered a 'knockout' to Merck KGaA - MSN
Immunome (NASDAQ:IMNM) Director Isaac Barchas Sells 383,200 Shares - MarketBeat
Guggenheim reiterates Buy rating on Immunome stock following $400M financing By Investing.com - Investing.com South Africa
Guggenheim reiterates Buy rating on Immunome stock following $400M financing - Investing.com Nigeria
Insider Buying: Clay Siegall Acquires Additional Shares of Immun - GuruFocus
Hedge Fund and Insider Trading News: Michael Hintze, Xavier Majic, Stanley Druckenmiller, Warren Buffett, Bill Ackman, Bridgewater Associates, Citadel Investment Group, Infini Capital, Immunome Inc (IMNM), White Mountains Insurance Group Ltd (WTM), a - Insider Monkey
Siegall buys Immunome (IMNM) shares worth $149k By Investing.com - Investing.com Nigeria
Immunome (NASDAQ:IMNM) Insider Purchases $204,900.00 in Stock - MarketBeat
Siegall buys Immunome (IMNM) shares worth $149k - Investing.com India
Tsai Philip buys $204,899 in Immunome stock By Investing.com - Investing.com South Africa
Tsai Philip buys $204,899 in Immunome stock - Investing.com
Immunome CTO Philip Tsai Buys 10,000 Shares - TradingView — Track All Markets
Will Immunome Inc. stock see insider buyingMarket Growth Summary & Verified Swing Trading Watchlist - Улправда
Clay Siegall Bought 5.8% More Shares In Immunome - simplywall.st
Immunome Chairman Acquires 5.8% More Stock - Yahoo Finance
Aug Breakouts: Will Immunome Inc. stock see insider buyingWeekly Profit Report & Free AI Powered Buy and Sell Recommendations - Улправда
How institutional buying supports Immunome Inc. stock2025 Biggest Moves & Fast Moving Stock Trade Plans - ulpravda.ru
Immunome Inc. Stock (IMNM) Opinions on Phase 3 RINGSIDE Trial Results - Quiver Quantitative
Is Immunome Inc. stock supported by strong fundamentalsPortfolio Return Report & Scalable Portfolio Growth Methods - Улправда
Can Immunome Inc. stock deliver strong Q4 earnings2025 Macro Impact & Low Volatility Stock Recommendations - DonanımHaber
Immunome’s Varegacestat shows dramatic results in Phase 3 desmoid tumor trial - Indian Pharma Post
Portfolio Recap: How institutional buying supports Immunome Inc. stockProduct Launch & AI Powered Buy/Sell Recommendations - ulpravda.ru
Aug Breakouts: Why Immunome Inc. stock remains resilient2025 Geopolitical Influence & AI Driven Price Forecasts - Улправда
Top Biotech Stocks To ConsiderDecember 15th - MarketBeat
Insider Buying: Clay Siegall Acquires 46,511 Shares of Immunome Inc (IMNM) - GuruFocus
Insider Buying: Immunome (NASDAQ:IMNM) CEO Acquires 46,511 Shares of Stock - MarketBeat
Immunome Insider Bought Shares Worth $999,987, According to a Recent SEC Filing - marketscreener.com
Immunome (IMNM) CEO and director buys shares in public offering - Stock Titan
Can Immunome Inc. stock hit analyst price targets2025 Growth vs Value & Accurate Technical Buy Alerts - ulpravda.ru
Latham & Watkins Advises on Immunome’s US$400 Million Public Offering - Legal Desire Media and Insights
Lifesci Capital Has Pessimistic View of Immunome Q3 Earnings - MarketBeat
Immunome Inc Azioni (IMNM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Immunome Inc Azioni (IMNM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Barchas Isaac | Director |
Dec 22 '25 |
Sale |
21.74 |
383,200 |
8,330,080 |
2,031,181 |
| SIEGALL CLAY B | President and CEO |
Dec 19 '25 |
Buy |
20.48 |
7,278 |
149,053 |
860,525 |
| Tsai Philip | Chief Technical Officer |
Dec 19 '25 |
Buy |
20.49 |
10,000 |
204,900 |
43,300 |
| SIEGALL CLAY B | President and CEO |
Dec 18 '25 |
Buy |
21.50 |
46,511 |
999,986 |
853,247 |
| Higgins Jack | Chief Scientific Officer |
Sep 10 '25 |
Option Exercise |
1.35 |
22,000 |
29,700 |
40,729 |
| BIENAIME JEAN JACQUES | Director |
Jun 03 '25 |
Buy |
9.38 |
5,000 |
46,900 |
36,415 |
| Higgins Jack | Chief Scientific Officer |
Mar 27 '25 |
Option Exercise |
1.35 |
5,200 |
7,020 |
18,729 |
| BIENAIME JEAN JACQUES | Director |
Mar 25 '25 |
Buy |
7.78 |
7,800 |
60,684 |
31,415 |
| SIEGALL CLAY B | President and CEO |
Mar 26 '25 |
Buy |
7.29 |
137,100 |
999,459 |
806,736 |
| BIENAIME JEAN JACQUES | Director |
Mar 24 '25 |
Buy |
8.21 |
7,000 |
57,470 |
23,615 |
0.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):